Literature DB >> 2867601

Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET.

L Farde, H Hall, E Ehrin, G Sedvall.   

Abstract

D2 dopamine receptors in the putamen of living human subjects were characterized by using the selective, high-affinity D2 dopamine receptor antagonist carbon-11-labeled raclopride and positron emission tomography. Experiments in four healthy men demonstrated saturability of [11C]raclopride binding to an apparently homogeneous population of sites with Hill coefficients close to unity. In the normal putamen, maximum binding ranged from 12 to 17 picomoles per cubic centimeter and dissociation constants from 3.4 to 4.7 nanomolar. Maximum binding for human putamen at autopsy was 15 picomoles per cubic centimeter. Studies of [11C]raclopride binding indicate that clinically effective doses of chemically distinct neuroleptic drugs result in 85 to 90 percent occupancy of D2 dopamine receptors in the putamen of schizophrenic patients.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2867601     DOI: 10.1126/science.2867601

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  126 in total

1.  Introduction. Ziprasidone appears to offer important therapeutic and tolerability advantages over conventional, and some novel, antipsychotics.

Authors:  R Tandon
Journal:  Br J Clin Pharmacol       Date:  2000       Impact factor: 4.335

2.  The utility of (11)C-arachidonate PET to study in vivo dopaminergic neurotransmission in humans.

Authors:  Madhav Thambisetty; Kathy A Gallardo; Jeih-San Liow; Lori L Beason-Held; John C Umhau; Abesh K Bhattacharjee; Margaret Der; Peter Herscovitch; Judith L Rapoport; Stanley I Rapoport
Journal:  J Cereb Blood Flow Metab       Date:  2011-12-14       Impact factor: 6.200

3.  Influence of phasic and tonic dopamine release on receptor activation.

Authors:  Jakob K Dreyer; Kjartan F Herrik; Rune W Berg; Jørn D Hounsgaard
Journal:  J Neurosci       Date:  2010-10-20       Impact factor: 6.167

4.  Maps of receptor binding parameters in the human brain--a kinetic analysis of PET measurements.

Authors:  G Blomqvist; S Pauli; L Farde; L Eriksson; A Persson; C Halldin
Journal:  Eur J Nucl Med       Date:  1990

5.  Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol.

Authors:  M Reimold; C Solbach; S Noda; J-E Schaefer; M Bartels; M Beneke; H-J Machulla; R Bares; T Glaser; H Wormstall
Journal:  Psychopharmacology (Berl)       Date:  2006-11-17       Impact factor: 4.530

6.  Clozapine binds preferentially to cortical D1-like dopamine receptors in the primate brain: a PET study.

Authors:  Yuan-Hwa Chou; Christer Halldin; Lars Farde
Journal:  Psychopharmacology (Berl)       Date:  2006-01-05       Impact factor: 4.530

7.  Characterization of [3H]nemonapride binding to mouse brain dopamine D2 receptors assessed in vivo and ex vivo for metabolic modeling in PET studies.

Authors:  K Ishiwata; K Inami; T Sasaki; T Nozaki; M Senda
Journal:  J Neural Transm Gen Sect       Date:  1994

8.  SERT and NET occupancy by venlafaxine and milnacipran in nonhuman primates: a PET study.

Authors:  Akihiro Takano; Christer Halldin; Lars Farde
Journal:  Psychopharmacology (Berl)       Date:  2012-10-23       Impact factor: 4.530

9.  Ventral striatal dopamine release in response to smoking a regular vs a denicotinized cigarette.

Authors:  Arthur L Brody; Mark A Mandelkern; Richard E Olmstead; Zoe Allen-Martinez; David Scheibal; Anna L Abrams; Matthew R Costello; Judah Farahi; Sanjaya Saxena; John Monterosso; Edythe D London
Journal:  Neuropsychopharmacology       Date:  2008-06-18       Impact factor: 7.853

10.  Measurement of density and affinity for dopamine D(2) receptors by a single positron emission tomography scan with multiple injections of [(11)C]raclopride.

Authors:  Yoko Ikoma; Hiroshi Watabe; Takuya Hayashi; Yoshinori Miyake; Noboru Teramoto; Kotaro Minato; Hidehiro Iida
Journal:  J Cereb Blood Flow Metab       Date:  2009-11-11       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.